12 Jan 2022 Biohaven enters exclusive license and research collaboration agreement with KU Leuven to advance first-in-class TRPM3 antagonists for the treatment of pain Member news
06 Jan 2022 Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
